Literature DB >> 20523835

Coexistence of amelanotic melanoma and liposarcoma.

Taek Jo Jeong1, Eun Ju Lee, Sik Haw, Min Kyung Shin, Choong Rim Haw.   

Abstract

An amelanotic malignant melanoma is characterized by little or no pigment. It is frequently misdiagnosed because it is a rare entity in general, and because of its unusual clinical features. Liposarcoma is one of the most common adult soft tissue sarcomas. We encountered a case of amelanotic melanoma with a concurrent liposarcoma. A 68-year-old man presented with a single, 1.5x1.5 cm round erythematous, eroded nodule on the left heel. A biopsy specimen showed atypical, pleomorphic tumor cells with little melanin pigment. The tumor cells were positive for S-100, HMB-45 and negative for cytokeratins. These findings were consistent with amelanotic melanoma. On positron emission tomography/computed tomography (PET/CT), a hypermetabolic lesion was found in the left buttock. This lesion was excised and diagnosed as a well-differentiated liposarcoma. An association between sarcomas and other primary malignancies has been reported. However, an association between melanoma and liposarcoma is rare.

Entities:  

Keywords:  Amelanotic melanoma; Liposarcoma

Year:  2009        PMID: 20523835      PMCID: PMC2861252          DOI: 10.5021/ad.2009.21.4.409

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  13 in total

1.  A Case of Amelanotic Subungual Melanoma.

Authors:  Sun Ji Kim; Hyun Jeong Park; Jun Young Lee; Baik Kee Cho
Journal:  Ann Dermatol       Date:  2008-03-31       Impact factor: 1.444

2.  Multiple primary malignancies in association with soft tissue sarcomas.

Authors:  O Merimsky; Y Kollender; J Issakov; J Bickels; G Flusser; M Gutman; D Lev-Chelouche; M Inbar; I Meller
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

3.  Introduction to the study of multiple primary cancers.

Authors:  J D Boice; H H Storm; R E Curtis; O M Jensen; R A Kleinerman; H S Jensen; J T Flannery; J F Fraumeni
Journal:  Natl Cancer Inst Monogr       Date:  1985-12

Review 4.  The INK4a/ARF locus and melanoma.

Authors:  E Sharpless; Lynda Chin
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

5.  Geographical variation in the penetrance of CDKN2A mutations for melanoma.

Authors:  D Timothy Bishop; Florence Demenais; Alisa M Goldstein; Wilma Bergman; Julia Newton Bishop; Brigitte Bressac-de Paillerets; Agnès Chompret; Paola Ghiorzo; Nelleke Gruis; Johan Hansson; Mark Harland; Nicholas Hayward; Elizabeth A Holland; Graham J Mann; Michela Mantelli; Derek Nancarrow; Anton Platz; Margaret A Tucker
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

6.  Cutaneous melanoma in Asian-Americans.

Authors:  Susanna Shin; Bryan E Palis; Jerri Linn Phillips; Andrew K Stewart; Roger R Perry
Journal:  J Surg Oncol       Date:  2009-02-01       Impact factor: 3.454

7.  Second primary malignancies among patients with soft tissue tumors in Sweden.

Authors:  Jianguang Ji; Kari Hemminki
Journal:  Int J Cancer       Date:  2006-08-15       Impact factor: 7.396

8.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

9.  Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features.

Authors:  M A Pizzichetta; R Talamini; I Stanganelli; P Puddu; R Bono; G Argenziano; A Veronesi; G Trevisan; H Rabinovitz; H P Soyer
Journal:  Br J Dermatol       Date:  2004-06       Impact factor: 9.302

10.  Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas.

Authors:  I Hostein; M Pelmus; A Aurias; F Pedeutour; S Mathoulin-Pélissier; J M Coindre
Journal:  J Pathol       Date:  2004-01       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.